Form 4: Pasithea Therapeutics Director Alfred J. Novak Increases Stake in Company

Director Alfred J. Novak reported purchasing additional shares of Pasithea Therapeutics Corp. (KTTA) on June 12 and 13, 2024.

Summary

• Alfred J. Novak, a director of Pasithea Therapeutics Corp. (KTTA), has reported the acquisition of additional shares of the company's common stock.
• On June 12, 2024, Novak purchased 750 shares at a weighted average price of $5.61 per share.
• The purchases on June 12 occurred in multiple transactions with prices ranging from $5.60 to $5.65.
• On June 13, 2024, Novak acquired another 2,750 shares at a weighted average price of $5.62 per share.
• The purchases on June 13 occurred in multiple transactions with prices ranging from $5.55 to $5.70.
• Following these transactions, Novak directly owns 3,500 shares of Pasithea Therapeutics Corp.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine disclosure, but insider buying can be interpreted as a positive signal.

Positives

• A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. The information is relevant to investors as it provides insight into the actions of company insiders.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive sign of confidence in the company's prospects.

Key Dates

Keywords

Pasithea Therapeutics Corp., KTTA, Alfred J. Novak, stock purchase, director, Form 4, beneficial ownership